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Thiazide diuretics enhance renal Na+ excretion by blocking the Na+-Cl– cotransporter (NCC), and mutations 
in NCC result in Gitelman syndrome. The mechanisms underlying the accompanying hypocalciuria and hypo-
magnesemia remain debated. Here, we show that enhanced passive Ca2+ transport in the proximal tubule rather 
than active Ca2+ transport in distal convolution explains thiazide-induced hypocalciuria. First, micropuncture 
experiments in mice demonstrated increased reabsorption of Na+ and Ca2+ in the proximal tubule during 
chronic hydrochlorothiazide (HCTZ) treatment, whereas Ca2+ reabsorption in distal convolution appeared 
unaffected. Second, HCTZ administration still induced hypocalciuria in transient receptor potential channel 
subfamily V, member 5–knockout (Trpv5-knockout) mice, in which active distal Ca2+ reabsorption is abolished 
due to inactivation of the epithelial Ca2+ channel Trpv5. Third, HCTZ upregulated the Na+/H+ exchanger, 
responsible for the majority of Na+ and, consequently, Ca2+ reabsorption in the proximal tubule, while the 
expression of proteins involved in active Ca2+ transport was unaltered. Fourth, experiments addressing the 
time-dependent effect of a single dose of HCTZ showed that the development of hypocalciuria parallels a 
compensatory increase in Na+ reabsorption secondary to an initial natriuresis. Hypomagnesemia developed 
during chronic HCTZ administration and in NCC-knockout mice, an animal model of Gitelman syndrome, 
accompanied by downregulation of the epithelial Mg2+ channel transient receptor potential channel subfam-
ily M, member 6 (Trpm6). Thus, Trpm6 downregulation may represent a general mechanism involved in the 
pathogenesis of hypomagnesemia accompanying NCC inhibition or inactivation.
Introduction
Thiazide diuretics are among the most commonly prescribed 
drugs, particularly in the treatment of arterial hypertension. These 
diuretics enhance renal Na+ excretion through inhibition of the 
Na+-Cl– cotransporter (NCC) present in the apical membrane of 
distal convoluted tubule (DCT) cells (1). In addition, these drugs 
are known to affect the Ca2+ and Mg2+ balance, inducing hypo-
calciuria and hypomagnesemia, respectively (2–7). Consequently, 
thiazides are frequently used in the treatment of idiopathic hyper-
calciuria and nephrolithiasis, disorders with a high incidence and 
socioeconomic burden in Western society (8–10). Furthermore, 
mutations in the gene encoding NCC have been shown to cause 
Gitelman syndrome, a recessive disorder with a phenotype that 
resembles the effects of chronic thiazide administration charac-
terized by hypocalciuria, renal Mg2+ wasting, and hypomagnese-
mia (4, 6, 11, 12). Intriguingly, the molecular mechanisms respon-
sible for the hypocalciuria and hypomagnesemia during thiazide 
administration and Gitelman syndrome remain elusive.
Two hypotheses prevail with respect to the Ca2+-sparing effect 
of thiazides (2, 4, 5, 13). First, renal salt and water loss due to thia-
zide treatment result in contraction of the extracellular volume 
(ECV), which triggers a compensatory increase in proximal Na+ 
reabsorption. This would in turn enhance the electrochemical 
gradient, driving passive Ca2+ transport in the proximal tubule (1, 
14). According to this line of reasoning, thiazide-induced hypo-
calciuria results from enhancement of passive paracellular Ca2+ 
reabsorption secondary to ECV contraction (2, 4, 7, 15). Second, 
microperfusion experiments suggested that acute administration 
of thiazides in the tubular lumen stimulates Ca2+ reabsorption 
in the distal convolution accessible to micropuncture (3). These 
accessible segments primarily consist of distal aspects of NCC-
expressing DCT (DCT2) as well as low- or non-NCC–expressing 
connecting tubule (CNT). Subsequently, several molecular mecha-
nisms were postulated to explain this latter stimulatory effect (2, 
4, 5, 16). These include hyperpolarization of the luminal plasma 
membrane and/or enhanced basolateral Na+/Ca2+ exchange due 
to a decreased intracellular Na+ concentration, both of which may 
increase apical Ca2+ entry through the epithelial Ca2+ channel tran-
sient receptor potential channel subfamily V, member 5 (Trpv5), 
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the expression of which is restricted to DCT2 and the CNT 
(15–19). Similar mechanisms were proposed to explain the hypo-
calciuria in Gitelman syndrome (4, 5).
Hypomagnesemia has been suggested to result from K+ defi-
ciency, increased passive Mg2+ secretion, or decreased active Mg2+ 
transport in the DCT (5, 6, 20). However, experimental evidence for 
either hypothesis is lacking. Studies have been seriously hampered 
by the fact that the exact mechanism responsible for active Mg2+ 
reabsorption has not been identified. Transient receptor potential 
channel subfamily M, member 6 (Trpm6) was recently identified 
as a Mg2+-permeable channel predominantly expressed along the 
apical membrane of the DCT (21–23). Mutations in Trpm6 were 
shown to cause autosomal recessive hypomagnesemia, character-
ized by inappropriately high fractional Mg2+ excretion rates and 
disturbed intestinal Mg2+ absorption (21, 22). This clearly sug-
gested that Trpm6 constitutes the apical entry step in active Mg2+ 
(re)absorption and provides an important new tool for studying 
this process on a molecular level.
Recently, transgenic mouse models were developed that might 
offer new insights into the pathogenesis of hypocalciuria and hypo-
magnesemia during thiazide treatment and in Gitelman syndrome. 
We generated Trpv5-knockout (Trpv5–/–) mice by ablation of the 
Trpv5 gene (24). These mice showed robust renal Ca2+ wasting, and 
micropuncture experiments illustrated that active Ca2+ 
reabsorption in distal convolution is effectively abolished. 
Thus, Trpv5–/– mice constitute a unique mouse model 
that can be used to unravel the relative contribution of 
passive and active Ca2+ reabsorption in thiazide-induced 
hypocalciuria. Furthermore, Schultheis et al. generated 
NCC-knockout (NCC–/–) mice exhibiting both hypocal-
ciuria and hypomagnesemia, which represent a valuable 
animal model that mimics Gitelman syndrome (25).
The aim of the present study was to elucidate the 
molecular mechanisms responsible for hypocalciuria 
and hypomagnesemia accompanying NCC inactivation. 
The effect of chronic hydrochlorothiazide (HCTZ) treat-
ment and the time-dependent effect of a single dose of 
HCTZ on urinary Ca2+ and Mg2+ excretion was evaluated 
in wild-type and Trpv5–/– mice. Tubular Na+ and Ca2+ 
handling was assessed by in vivo free-flow micropunc-
ture experiments in control and HCTZ-treated wild-type 
mice. In addition, an extensive evaluation of the 
renal expression level of Na+, Ca2+, and Mg2+ trans-
port proteins was performed in vehicle and HCTZ-
treated wild-type and Trpv5–/– mice. Moreover, the 
renal expression of the epithelial Mg2+ channel 
Trpm6 was assessed in NCC–/– mice.
Results
Metabolic studies in HCTZ-treated Trpv5+/+ and Trpv5–/– 
mice. The metabolic data obtained during chronic 
administration of HCTZ (25 mg/kg/d during 6 
days) in Trpv5+/+ and Trpv5–/– mice are shown in 
Tables 1 and 2. Genetic ablation of Trpv5 in mice 
resulted in a calciuria that was about 6-fold higher 
than that in Trpv5+/+ mice (Table 1) (24). Important-
ly, HCTZ treatment significantly decreased urinary 
Ca2+ excretion in Trpv5+/+ as well as Trpv5–/– mice. 
Serum Ca2+ levels were not affected by HCTZ in 
Trpv5+/+ mice but significantly increased in Trpv5–/– 
mice. In addition, HCTZ treatment significantly enhanced urinary 
Mg2+ excretion in Trpv5+/+ mice. Serum Mg2+ levels were signifi-
cantly reduced in HCTZ-treated wild-type mice. Urine volume was 
increased by HCTZ treatment in the Trpv5+/+ mice, whereas diure-
sis in HCTZ-treated Trpv5–/– mice did not differ from that in non-
treated controls. Furthermore, overall Na+ excretion was unaltered 
by chronic HCTZ treatment in wild-type as well as Trpv5–/– mice, 
and GFR was not affected, as shown by the creatinine clearance 
(CCr). HCTZ treatment significantly decreased endogenous lith-
ium clearance (CLi), an inverse measure of proximal tubular Na+ 
reabsorption and, thereby, passive paracellular Ca2+ transport in 
the proximal tubule. Urinary pH was not affected by HCTZ treat-
ment in wild-type mice, whereas HCTZ neutralized the acidic uri-
nary pH in Trpv5–/– mice. HCTZ significantly increased hematocrit 
in Trpv5+/+ and Trpv5–/– mice, and body weight was reduced com-
pared with their respective controls (Table 2). Serum Na+, K+, and 
creatinine levels were not influenced by HCTZ treatment.
Renal mRNA and protein expression of Ca2+, Mg2+, and Na+ transport-
ers. Ca2+, Mg2+, and Na+ transport protein mRNA expression levels 
were determined by real-time quantitative PCR analysis, and protein 
abundance was determined by immunohistochemistry (Figures 1 
and 2). HCTZ did not affect the mRNA expression levels of the api-
cally localized epithelial Ca2+ channel Trpv5 in wild-type mice (Figure 
Table 1
Urine analysis of vehicle and HCTZ-treated Trpv5+/+ and Trpv5–/– mice
 Trpv5+/+ Trpv5–/–
 Controls HCTZ Controls HCTZ
Urine volume (ml/24 h) 5.2 ± 0.9 6.9 ± 1.4A 13.0 ± 1.7 10.8 ± 0.2
Ca2+ excretion (μmol/24 h) 41 ± 2 34 ± 2A 273 ± 10 169 ± 13B
Ca2+/creatinine 0.29 ± 0.02 0.15 ± 0.02A 1.96 ± 0.06 1.17 ± 0.14B
Mg2+ excretion (μmol/24 h) 26 ± 14 85 ± 9A nd nd
Mg2+/creatinine 0.2 ± 0.1 0.6 ± 0.1A nd nd
Na+ excretion (μmol/24 h) 751 ± 67 757 ± 50 780 ± 25 777 ± 11
Urinary pH 7.1 ± 0.1 6.8 ± 0.2 6.0 ± 0.1 6.9 ± 0.1B
CCr (ml/min) 0.24 ± 0.04 0.24 ± 0.01 0.27 ± 0.01 0.26 ± 0.03
CLi (μl/min) 13.5 ± 0.6 9.8 ± 0.2A 13.9 ± 0.7 10.1 ± 0.5A
Controls, animals receiving vehicle only; HCTZ, animals receiving 25 mg/kg/d HCTZ; nd, 
not determined. Data are presented as mean ± SEM. AP < 0.05 versus vehicle-treated 
Trpv5+/+; BP < 0.05 versus vehicle-treated Trpv5–/–.
Table 2
Serum analysis and body weight of vehicle and HCTZ-treated Trpv5+/+ and 
Trpv5–/– mice
 Trpv5+/+ Trpv5–/–
 Controls HCTZ Controls HCTZ
Serum
 [Ca2+] (mmol/l) 2.47 ± 0.01 2.46 ± 0.03 2.36 ± 0.02 2.44 ± 0.02B
 [Mg2+] (mmol/l) 0.86 ± 0.01 0.80 ± 0.01A nd nd
 [Na+] (mmol/l) 100 ± 4 104 ± 3 100 ± 1 103 ± 3
 [K+] (mmol/l) 5.2 ± 0.2 5.3 ± 0.1 5.1 ± 0.1 5.1 ± 0.1
 [Creatinine] (μmol/l) 34 ± 1 36 ± 1 37 ± 1 35 ± 1
 Hematocrit (%) 52 ± 1 57 ± 1A 52 ± 1 55 ± 1B
Weight loss (mg) 1.0 ± 0.1 1.5 ± 0.1A 0.2 ± 0.1 0.7 ± 0.2B
Data are presented as mean ± SEM. AP < 0.05 versus vehicle-treated Trpv5+/+;  
BP < 0.05 versus vehicle-treated Trpv5–/–.
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1A), nor did it affect Trpv5 protein levels in the DCT and CNT (Fig-
ure 2A). Renal mRNA and protein levels of the cytosolic Ca2+-binding 
protein calbindin-D28K were significantly decreased in Trpv5–/– mice 
compared with their wild-type littermates (Figure 1B and Figure 2B). 
Likewise, mRNA expression of the basolateral Na+/Ca2+ exchanger 1 
(NCX1) was reduced in these mice. However, HCTZ administration 
did not significantly alter calbindin-D28K and NCX1 expression in 
both Trpv5+/+ and Trpv5–/– mice (Figure 1, B and C, and Figure 2B). 
This unaffected calbindin-D28K protein expression was confirmed by 
semiquantitative immunoblotting (89% ± 11% and 106% ± 11% of 
nontreated Trpv5+/+ and Trpv5–/– controls, respectively).
In general, passive Ca2+ reabsorption is driven by the electro-
chemical gradient generated by transcellular Na+ transport. 
Therefore, we determined Na+/H+ exchanger (NHE3) and Na+-
K+-2Cl– cotransporter (NKCC2) expression as indirect measures 
of passive paracellular Ca2+ transport in the proximal tubule and 
thick ascending limb of Henle (TAL), respectively. In accordance 
with the decreased CLi, proximal tubular NHE3 protein expression 
was significantly increased in HCTZ-treated Trpv5+/+ and Trpv5–/– 
mice (Figure 2D). In contrast, the level of renal NKCC2 mRNA 
expression, which is exclusively expressed in TAL, was not affected 
by HCTZ treatment (Figure 1D).
Figure 1
Effect of chronic HCTZ treatment on renal mRNA expression levels of 
Ca2+ and Na+ transport proteins in Trpv5+/+ and Trpv5–/– mice. Renal 
mRNA expression levels of the epithelial Ca2+ channel Trpv5 (A), 
calbindin-D28K (B), NCX1 (C), and NKCC2 (D) were determined by 
real-time quantitative PCR analysis and are depicted as the ratio to 
hypoxanthine-guanine phosphoribosyl transferase (HPRT). Black 
bars, vehicle-treated; white bars, HCTZ-treated, 25 mg/kg/d during 
6 days. n = 9 animals per treatment group. Data are presented as 
mean ± SEM. #P < 0.05 versus vehicle-treated Trpv5+/+.
Figure 2
Effect of chronic HCTZ treatment on renal protein abundance of Ca2+ and Na+ transport proteins in Trpv5+/+ and Trpv5–/– mice. Protein abun-
dance was determined by computerized analysis of immunohistochemical images and is presented as integrated optical density (IOD; AU) for 
the epithelial Ca2+ channel Trpv5 (A), calbindin-D28K (B), NCC (C), and NHE3 (D). Black bars, vehicle-treated (CTR); white bars, HCTZ-treated, 
25 mg/kg/d during 6 days; +/+ CTR and +/+ HCTZ, vehicle- and HCTZ-treated Trpv5+/+ mice, respectively; –/– CTR and –/– HCTZ, vehicle- and 
HCTZ-treated Trpv5–/– mice, respectively. n = 9 animals per treatment group. Data are presented as mean ± SEM. *P < 0.05 versus respective 
vehicle-treated controls; #P < 0.05 versus vehicle-treated Trpv5+/+.
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Interestingly, HCTZ treatment significantly reduced mRNA 
expression and protein abundance of the epithelial Mg2+ chan-
nel Trpm6 in wild-type mice (Figure 3, A and B). To confirm the 
viability of the DCT and thereby the specificity of the Trpm6 
downregulation, we determined NCC protein expression by 
immunohistochemical analysis (Figure 2C). NCC protein abun-
dance was significantly increased in HCTZ-treated Trpv5+/+ 
and Trpv5–/– mice. This was confirmed by semiquantitative 
immunoblotting (153% ± 20% and 143% ± 11% of nontreated 
Trpv5+/+ and Trpv5–/– controls, respectively). Of note, deleterious 
effects or apoptotic alterations in the DCT were not detected by 
immunohistochemical or light microscopical analysis of HCTZ-
treated mice as reported previously (7, 26).
Renal expression of the epithelial Mg2+ channel Trpm6 in NCC–/– mice. 
Mice lacking NCC display a phenotype similar to the effects of 
chronic thiazide administration, including hypocalciuria and 
hypomagnesemia (25). Therefore, the renal expression of Trpm6 
was determined in NCC+/+ and NCC–/– mice. Renal Trpm6 mRNA 
expression was significantly reduced in NCC–/– mice (Figure 4A). 
Furthermore, immunohistochemical analysis revealed that Trpm6 
protein abundance along the apical membrane of the DCT is pro-
foundly decreased in these mice (Figure 4B).
Time-dependent effect of a single dose of HCTZ in wild-type and Trpv5–/– 
mice. To further evaluate the time-dependent effect of thiazides on 
Na+, Ca2+ and Mg2+ excretion and their interdependency, additional 
metabolic cage experiments were performed. Figure 5 summarizes 
the effect of a single dose of HCTZ on Na+ and Ca2+ excretion 6, 12, 
and 24 hours after administration. During the first 6 hours after 
HCTZ administration, Na+ excretion was significantly increased in 
Trpv5+/+ and Trpv5–/– mice (433% ± 16% and 414% ± 17%, respec-
tively). In contrast, the urinary excretion of Ca2+ was unaffected 
(109% ± 11% and 95% ± 3%, respectively). However, during the next 
6 hours, Na+ excretion was significantly decreased in both HCTZ-
treated Trpv5+/+ and Trpv5–/– mice compared with their correspond-
ing controls (54% ± 11% and 55% ± 3%, respectively). Importantly, 
within this latter time period a significant hypocalciuria developed 
in HCTZ-treated Trpv5+/+ as well as Trpv5–/– mice (44% ± 3% and 
46% ± 6%, respectively). Thus, the Ca2+-sparing effect resulting from 
a single dose of HCTZ coincides with a period of increased renal 
Na+ reabsorption. Furthermore, while absolute Ca2+ excretion dif-
fered between Trpv5+/+ and Trpv5–/– mice, the overall effect of HCTZ 
administration was identical in Trpv5+/+ and Trpv5–/– mice. Mg2+ 
excretion was unaffected by a single dose of HCTZ during the 24 
hours after its administration (data not shown).
In vivo free-flow micropuncture studies in HCTZ-treated mice. We per-
formed micropuncture experiments in control and HCTZ-treated 
(25 mg/kg/d during 6 days) wild-type mice in order to directly 
evaluate tubular Na+ and Ca2+ handling in response to chronic thi-
azide treatment. No significant differences were observed between 
HCTZ-treated mice and control mice with regard to mean arterial 
blood pressure (93 ± 4 vs. 87 ± 3 mmHg; n = 5–6 mice), single neph-
ron GFR from distal (7.3 ± 0.8 vs. 6.9 ± 0.5 nl/min; n = 10 nephrons 
per group) or proximal tubular collections (6.8 ± 0.3 vs. 6.9 ± 0.3 nl/
min; n = 17–21 nephrons per group). Similarly, the amounts of Na+ 
and Ca2+ filtered per nephron were not different between HCTZ-
treated and control mice (1,146 ± 44 vs. 1,181 ± 50 pmol/min and 
15.2 ± 0.5 vs. 15.9 ± 0.7 pmol/min, respectively). Reabsorption of 
Na+, fluid, and Ca2+ up to the last surface loop of the proximal 
tubule, however, was significantly greater in HCTZ-treated than 
in control mice (Figure 6A). As a consequence, the absolute deliv-
ery of Ca2+ to the late proximal tubule was significantly lower in 
HCTZ-treated mice (5.4 ± 0.4 vs. 6.9 ± 0.4 pmol/min). Absolute 
and fractional delivery of Ca2+ to the distal convolution accessible 
to micropuncture was likewise significantly lower in HCTZ-treat-
ed versus control mice (0.21 ± 0.03 vs. 0.71 ± 0.18 pmol/min and 
Figure 3
Effect of chronic HCTZ treatment on renal mRNA expression and pro-
tein abundance of the epithelial Mg2+ channel Trpm6. (A) Renal mRNA 
expression levels of the epithelial Mg2+ channel Trpm6 were determined 
by real-time quantitative PCR analysis and are depicted as the ratio to 
HPRT. (B) Trpm6 protein abundance was determined by computerized 
analysis of immunohistochemical images and is presented as integrat-
ed optical density (AU). HCTZ, 25 mg/kg/d HCTZ for 6 days. n = 9 per 
treatment group. Data are presented as mean ± SEM. *P < 0.05 versus 
vehicle-treated controls.
Figure 4
Renal mRNA expression and protein abundance of the epithelial Mg2+ 
channel Trpm6 in NCC+/+ and NCC–/– mice. (A) Renal mRNA expres-
sion levels of the epithelial Mg2+ channel Trpm6 were determined by 
real-time quantitative PCR analysis and are depicted as the ratio to 
HPRT. (B) Trpm6 protein abundance was determined by computer-
ized analysis of immunohistochemical images and is presented as 
integrated optical density (AU). n = 6 animals per genotype. Data are 
presented as mean ± SEM. *P < 0.05 versus NCC+/+ mice.
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1.6% ± 0.3% vs. 4.4% ± 1.0%). Since K+ secretion occurs along the dis-
tal part of the nephron accessible to micropuncture (together with 
water reabsorption in the CNT and cortical collecting duct [CCD]), 
the distal luminal concentration of K+ was used as an indicator of 
the distal collection site. Consistent with intact Ca2+ reabsorption 
along the distal convolution and confirming previous experiments 
which related fractional Ca2+ delivery in distal convolution to lumi-
nal K+ concentration (24), both HCTZ-treated and control mice 
showed a rapid fall in fractional Ca2+ delivery with increasing lumi-
nal concentrations of K+ (Figure 6B). The fractional delivery of Ca2+ 
to the early distal convolution, identified by low tubular fluid K+ 
concentrations, however, appeared reduced in HCTZ-treated versus 
control mice (about 4% vs. 10%). This indicates that the Ca2+-spar-
ing effect of chronic HCTZ administration localizes upstream to 
the distal convolution accessible to micropuncture, i.e. proximal to 
the site of Trpv5-mediated active Ca2+ reabsorption (24).
Discussion
The present study demonstrates that enhanced passive Ca2+ trans-
port in the proximal tubule due to ECV contraction explains the 
hypocalciuria that develops during chronic thiazide treatment. Of 
crucial importance is that micropuncture experiments in HCTZ-
treated mice demonstrated increased reabsorption of Na+ and 
Ca2+ in the proximal tubule, whereas Ca2+ reabsorption in the dis-
tal convolution accessible to micropuncture, which includes the 
site of Trpv5-mediated active Ca2+ reabsorption, was unaffected. 
Furthermore, we showed that thiazide-induced hypocalciuria can 
be elicited in Trpv5–/– mice, in which active Ca2+ reabsorption is 
abolished. In line with these data, we showed that the hypocal-
ciuric response to thiazides parallels a compensatory increase in 
renal Na+ reabsorption secondary to an initial natriuresis. Chronic 
thiazide administration enhanced Mg2+ excretion and specifical-
ly reduced renal expression levels of the epithelial Mg2+ channel 
Trpm6. In addition, Trpm6 expression was severely decreased in 
NCC–/– mice. Therefore, the pathogenesis of hypomagnesemia in 
chronic thiazide treatment as well as Gitelman syndrome appears 
to involve Trpm6 downregulation.
ECV contraction is a known stimulus for paracellular Ca2+ 
reabsorption in the proximal tubule (2, 14). Hypovolemia triggers 
a compensatory increase of proximal Na+ reabsorption, which in 
turn enhances the electrochemical gradient driving passive Ca2+ 
transport in proximal tubular segments (1, 2, 14). HCTZ-treated 
mice exhibited a significant increase in hematocrit and concomi-
tant decrease in body weight compared with nontreated controls, 
which confirms that ECV contraction occurred. Importantly, 
micropuncture experiments showed that HCTZ increases Ca2+ 
reabsorption in the proximal tubule, which results in decreased 
Ca2+ delivery to the last surface loop of the proximal tubule and 
to the first surface loop of the distal convolution. This was asso-
ciated with an increased fractional Na+ reabsorption rate in the 
proximal tubule, as further substantiated by the reduced CLi in 
HCTZ-treated mice. In line with these data, chronic HCTZ treat-
ment upregulated expression of NHE3, which is responsible for 
the majority of Na+ reabsorption in proximal tubules and thus 
provides the main driving force for passive Ca2+ reabsorption. 
Alternatively, thiazide-induced hypocalciuria has been previ-
ously attributed to increased active Ca2+ reabsorption. However, 
the in vivo micropuncture experiments indicated similar or even 
reduced absolute Ca2+ reabsorption along the accessible distal 
convolution of HCTZ-treated versus control mice, whereas Ca2+ 
delivery to the early accessible distal convolution was decreased by 
HCTZ treatment. Previous micropuncture studies in distal con-
volutions of mice lacking Trpv5 revealed that Ca2+ reabsorption 
Figure 5
Time-dependent effects of HCTZ on urinary Na+ and Ca2+ excretion 
in Trpv5+/+ and Trpv5–/– mice. Trpv5+/+ and Trpv5–/– mice were housed 
in metabolic cages, and urine was sampled 6, 12, and 24 hours after 
the intraperitoneal administration of vehicle or 25 mg/kg HCTZ. Arrow-
head indicates administration of a single dose of 25 mg/kg HCTZ. 
Filled squares, vehicle-treated Trpv5+/+; open squares, HCTZ-treated 
Trpv5+/+; filled triangles, vehicle-treated Trpv5–/–; open triangles, HCTZ-
treated Trpv5–/–. n = 9 animals per treatment group. Data are presented 
as mean ± SEM; absolute values were normalized to respective vehi-
cle-treated controls. *P < 0.05 versus vehicle-treated Trpv5+/+ mice. 
#P < 0.05 versus vehicle-treated Trpv5–/– mice.
Figure 6
Effect of chronic HCTZ treatment in mice on Ca2+ transport along the 
single nephron assessed by in vivo free-flow micropuncture. (A) Frac-
tional reabsorption of Na+, fluid, and Ca2+ up to the last surface loop of 
the proximal tubule. (B) Relation between K+ concentration in tubular 
fluid of distal convolution and fractional Ca2+ delivery to these sites. 
Low K+ concentrations indicate early puncture sites, and high K+ con-
centrations indicate late puncture sites of distal convolution. Black bars 
and filled circles, vehicle-treated controls; white bars and open circles, 
HCTZ, 25 mg/kg/d during 6 days. n = 10 nephrons for distal collections 
and n = 17–21 nephrons for proximal collections in 5–6 mice per treat-
ment group. Data are presented as mean ± SEM. *P < 0.05 versus 
vehicle-treated controls.
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is normal up to the early accessible sites but becomes abolished 
along the downstream accessible segments of distal convolution 
(24). This indicated that no Trpv5-mediated Ca2+ reabsorption 
occurs upstream to the early sites accessible to micropuncture, 
which is consistent with the localization of Trpv5 in DCT2 and 
the CNT (17, 24). Thus, the reduced delivery of Ca2+ to the early 
accessible distal convolution in HCTZ-treated mice cannot be the 
result of Trpv5-mediated active Ca2+ reabsorption. In accordance 
with these findings, chronic HCTZ administration still decreased 
urinary Ca2+ excretion in mice lacking Trpv5, in which active Ca2+ 
transport in the distal convolution is effectively abolished (24). 
This is further exemplified by the severe downregulation of the 
remaining Ca2+ transport proteins in Trpv5–/– mice, which was 
unaffected by HCTZ treatment. Together with the micropuncture 
data, these results indicate that the Ca2+-sparing effect of thiazides 
can be explained neither by increased Ca2+ entry through Trpv5 
nor by enhanced active Ca2+ transport in general. Additional exper-
iments investigating the time dependency of these HCTZ effects 
demonstrated that Ca2+ excretion is unaltered during the natri-
uretic response following HCTZ administration, again indicating 
that direct stimulation of active Ca2+ reabsorption by inhibition of 
NCC does not occur. In contrast, a profound decrease in urinary 
Ca2+ excretion followed the initial natriuresis and, importantly, 
paralleled a reduced net Na+ excretion. In line with the present 
data, we previously demonstrated that volume contraction mimics 
thiazide-induced hypocalciuria and volume repletion completely 
reverses this hypocalciuria in rats (7). In conclusion, these data 
demonstrate that enhanced proximal tubular Na+ transport, as 
a consequence of ECV contraction, stimulates paracellular Ca2+ 
transport and constitutes the molecular mechanism underlying 
thiazide-induced hypocalciuria.
Gitelman syndrome is an autosomal recessive disorder caused by 
loss-of-function mutations in the gene encoding NCC, with a phe-
notype resembling chronic thiazide administration (4, 11). Loffing 
et al. recently demonstrated that renal Trpv5 and NCX1 expression 
are unaffected in NCC–/– mice, which display hypocalciuria (25, 27). 
Accordingly, micropuncture experiments in NCC–/– mice showed 
that active Ca2+ reabsorption is unaltered in distal convolution but 
that fractional absorption of both Na+ and Ca2+ in the proximal 
tubule is increased (27). The latter observation is in line with the 
enhancement of passive Ca2+ reabsorption through increased Na+ 
reabsorption in the proximal tubule, with results similar to the 
micropuncture data obtained during chronic HCTZ treatment in 
the present study. Taken together, our studies demonstrate that 
increased passive Ca2+ reabsorption in the proximal tubule explains 
the Ca2+-sparing effect of both NCC inhibition and inactivation.
Previously, we showed that thiazide-induced hypocalciuria 
occurs in spite of reduced renal expression of Ca2+ transport pro-
teins in the rat (7). In these experiments a significantly higher 
dose of HCTZ was administered compared with that in the pres-
ent study. Loffing et al. previously showed structural damage to 
and loss of DCT cells during thiazide administration with equiva-
lently high doses, and, therefore, we hypothesized that apoptosis 
explains the reduced expression levels (7, 26). However, this was 
never observed in thiazide-treated mice. In the past, we have tried 
to reproduce the observed apoptotic changes in mice using several 
mouse strains, both sexes of mice, and different thiazide diuret-
ics and application protocols but were never able to produce any 
DCT cell apoptosis in mice (J. Loffing, unpublished observations). 
Accordingly, deleterious effects were not detected in the present 
study, and the increased NCC expression in HCTZ-treated animals 
points to the viability of the DCT (28, 29). However, both stud-
ies consistently show that thiazide-induced hypocalciuria persists 
despite the absence or reduced abundance of proteins essentially 
responsible for active Ca2+ transport.
Interestingly, Trpv5–/– mice displayed significant polyuria and 
acidic urinary pH, which facilitate the excretion of large quanti-
ties of Ca2+ by reducing the risk of Ca2+ precipitations (24, 30–32). 
HCTZ administration increased diuresis in wild-type animals but 
did not alter urine volume in Trpv5–/– mice. Furthermore, HCTZ 
normalized the acidic urinary pH in Trpv5–/– mice. It has been dem-
onstrated that a high luminal Ca2+ concentration, by activating 
the Ca2+-sensing receptor in the apical membrane of the collect-
ing duct, blunts water permeability through aquaporin-2 (33, 34). 
Therefore, the Ca2+-sparing effect of HCTZ might counteract the 
hypercalciuria-induced polyuria and remove the necessity for urine 
acidification in Trpv5–/– mice, which would suggest that the distal 
Ca2+ load directly influences urine volume and acidification in an 
effort to prevent kidney stone formation.
Hypomagnesemia, as a side-effect of chronic thiazide admin-
istration and a defining feature of Gitelman syndrome, remains 
unexplained. Chronic HCTZ administration increased urinary 
Mg2+ excretion in the presence of reduced serum Mg2+ levels while 
GFR remained unaffected, which confirms that the hypomagnese-
mia is due to renal Mg2+ wasting. Importantly, renal Trpm6 expres-
sion was reduced in HCTZ-treated animals, while NCC expression 
was enhanced, which illustrates that Trpm6 downregulation is a 
specific nondeleterious effect. Trpm6 constitutes a Mg2+-perme-
able channel localized along the apical membrane of the DCT to 
which active Mg2+ reabsorption is restricted (21–23). Mutations 
in Trpm6 were shown to be associated with renal Mg2+ wasting 
(21, 22). Furthermore, we previously demonstrated a similarly 
reduced Trpm6 expression in tacrolimus-induced hypomagnese-
mia (35). Thus, the present data suggested that chronic thiazide 
treatment results in a similar defect in active Mg2+ reabsorption. 
As Trpm6 and NCC exactly colocalize in the DCT, a direct inhibi-
tory effect of decreased NaCl influx on active Mg2+ transport could 
in principle be involved (23). However, whereas Ca2+ reabsorption 
was diminished upon a single dose of HCTZ, urinary Mg2+ excre-
tion remained unaltered within 24 hours after HCTZ administra-
tion, which contradicts the hypothesis that Mg2+ reabsorption is 
directly inhibited. This dissociation of Ca2+ and Mg2+ excretion 
can be explained when the relative contribution of the proximal 
tubule and the TAL in the passive reabsorption of these divalents 
is taken into account. The majority of Mg2+ is reabsorbed in the 
TAL due to the driving force generated by NKCC2-mediated NaCl 
reabsorption, while micropuncture studies have shown that thia-
zides particularly enhance proximal tubule Na+ transport (14, 36). 
Accordingly, we showed that HCTZ increases proximal tubular 
NHE3 expression without affecting the NKCC2 expression. Hypo-
thetically, an additional defect of Mg2+ reabsorption in TAL could 
explain the increased Mg2+ excretion in HCTZ treatment. However, 
inborn as well as acquired defects in TAL Mg2+ reabsorption are 
consistently accompanied by hypercalciuria, which renders this 
hypothesis unfeasible when the Ca2+-sparing effect of thiazides is 
taken into account (37–40). In line with the data obtained dur-
ing HCTZ administration, NCC–/– mice were also shown to dis-
play hypomagnesemia in the absence of hypokalemia (4, 25). In 
the present study we report that, similar to what occurs during 
chronic thiazide administration, renal Trpm6 abundance in the 
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DCT is significantly reduced in NCC–/– mice. Therefore, Trpm6 
downregulation may represent a general mechanism involved in 
the pathogenesis of hypomagnesemia in both Gitelman syndrome 
and chronic thiazide administration.
NCC–/– mice were previously shown to display widespread atro-
phy of DCT cells (27). This marked reduction in DCT plasma 
membrane area and, thereby, apical expression of Mg2+ channels 
could explain the observed renal Mg2+ wasting. As discussed above, 
deleterious effects of chronic thiazide administration particularly 
on DCT1 were previously suggested but did not occur in the pres-
ent study (7, 26). Thus, at present it is unknown which mecha-
nism is responsible for the observed Trpm6 downregulation. In 
this respect, it is interesting to note that aldosterone excess has 
been shown to be associated with renal Mg2+ wasting, whereas 
hypermagnesemia may accompany aldosterone deficiency (4, 41). 
In addition, it has been shown that the mineralocorticoid recep-
tor antagonist spironolactone reduces urinary Mg2+ excretion 
in patients with Gitelman syndrome (42, 43). During thiazide-
induced ECV contraction as well as in NCC–/– mice, aldosterone 
levels are increased (25). Therefore, hyperaldosteronism might 
hypothetically downregulate Trpm6 expression and, thereby, 
result in renal Mg2+ wasting.
In conclusion, this study addressing the mechanism underlying 
thiazide-induced hypocalciuria answers a long-standing question 
in physiology and medicine. Furthermore, it offers new insights 
concerning the hypomagnesemia accompanying chronic thiazide 
treatment and Gitelman syndrome.
Methods
Animal studies in Trpv5–/– and NCC–/– mice
Experiment 1. Trpv5–/– mice were recently generated by targeted ablation 
of the Trpv5 gene (24). In short, the Trpv5 gene was cloned from a 129/Sv 
mouse genomic library and subcloned in a modified neomycin-loxP–tar-
geting vector. Eventually, a recombinant ES cell line was used to gener-
ate chimeras, which allowed germline transmission of the mutant allele 
(Trpv5loxneo). Heterozygous (Trpv5+/–) mice, harboring 1 null allele, were 
obtained by breeding Trpv5loxneo mice with a germline Ella-cre-deletor strain 
(44). The offspring of Trpv5+/– mice were genotyped by PCR as described 
previously (44). Eight-week old male Trpv5+/+ and Trpv5–/– littermates were 
kept in a light- and temperature-controlled room with ad libitum access 
to deionized drinking water and standard pelleted chow (0.25% [wt/vol] 
NaCl; 1% [wt/vol] Ca; 0.2% [wt/vol] Mg). Mice were randomly assigned to 
either the control or HCTZ treatment group. Control animals received 
daily intraperitoneal injections of vehicle only. HCTZ was administered 
by intraperitoneal injection of 25 mg/kg/d. Mice were treated for 6 days, 
after which they were housed in metabolic cages, which enabled 24-hour 
collection of urine samples. At the end of the experiment, blood samples 
were taken, and the animals were sacrificed. Subsequently, kidney and duo-
denum were sampled.
Experiment 2. A second metabolic study was performed to study the 
effects of a single dose of HCTZ at various time intervals after administra-
tion. To this end, Trpv5+/+ and Trpv5–/– littermates were housed in metabol-
ic cages, and urine was collected 6, 12, and 24 hours after administration 
of vehicle. One week later, the mice were intraperitoneally injected with a 
single dose of 25 mg/kg HCTZ. Likewise, urine was collected 6, 12, and 24 
hours thereafter, which enabled analysis of the time-dependent effects of 
HCTZ on Na+, Ca2+, and Mg2+ excretion.
Experiment 3. NCC–/– mice were generated and characterized as described 
previously by Schultheis et al. (25). NCC+/+ and NCC–/– mice had ad libitum 
access to drinking water and standard pelleted chow (0.24% [wt/vol] NaCl; 
1% [wt/vol] Ca; 0.2% [wt/vol] Mg); after animals were sacrificed, kidneys 
were sampled for determination of renal Trpm6 mRNA expression and 
protein abundance. The animal ethics board of the Radboud University 
Nijmegen Medical Centre approved the animal studies.
Analytical procedures
We determined serum and urine Ca2+ and Mg2+ concentrations using a 
colorimetric assay as described previously (45). We measured serum and/or 
urine Na+, Cl–, K+, and creatinine concentrations using a Hitachi autoana-
lyzer (Hitachi Corp.). A flame spectrophotometer (FCM 6343; Eppendorf) 
was used to measure serum and urine Li+ concentrations. We determined 
hematocrit using a standard centrifugation protocol (46).
Real-time quantitative PCR
Total RNA was extracted from kidney and duodenum and reverse tran-
scribed as described previously (7, 47). The obtained cDNA was used to 
determine Trpv5, calbindin-D28K, NCX1, Trpm6, NKCC2, and hypoxan-
thine-guanine phosphoribosyl transferase mRNA levels in kidney by real-
time quantitative PCR, as described previously (48). NKCC2 forward and 
reverse primer sequences, respectively, were 5′-CCTATGTGAGTGCTT-
TAGACAACGCTCTGGA-3′ and 5′-GGCTCCTCCACACAGGCTC-3′, and 
the sequence for the fluorescent probe (5′FAM-3′TAMRA) was 5′-CACAT-
GGTCTTCCACTGTGGTT-3′. In the case of Trpm6, these were 5′-CCTG-
GTCTGAGGATGATGTTCTCAAGCC-3′, 5′-AAAGCCATGCGAGTTAT 
CAGC-3′, and 5′-CTTCACAATGAAAACCTGCCC-3′.
Immunohistochemistry and immunoblotting
Staining of kidney sections for Trpv5, calbindin-D28K Trpm6, NCC, 
and NHE3 was performed on 7-μm cryosections of periodate-lysine-
paraformaldehyde–fixed kidney samples. Sections were stained with guinea 
pig anti-Trpv5 (17), mouse anti–calbindin-D28K (Swant), affinity-purified 
guinea pig anti-Trpm6 (23), rabbit anti-NCC (7), and rabbit anti-NHE3 
(49), as described previously (24, 35). Images were made using a Zeiss flu-
orescence microscope equipped with a digital photo camera (DMX1200; 
Nikon). For semiquantitative determination of protein levels, images were 
analyzed with the Image-Pro Plus 4.1 image analysis software (MediaCyber-
netics), and protein levels were quantified as the mean of integrated opti-
cal density. Of note, in the case of NHE3 specifically, the immunopositive 
signal in kidney cortex was quantified, which represents proximal tubular 
NHE3 expression. Semiquantitative immunoblotting for calbindin-D28K 
and NCC was performed as described previously (7). Immunopositive 
bands were scanned and pixel density was determined using the Image-Pro 
4.1 image analysis software.
In vivo free-flow micropuncture experiments  
in HCTZ-treated wild-type mice
Male C57BL/6 mice were randomly assigned to control or chronic HCTZ 
treatment as described in experiment 1. After day 6 of treatment, the left 
kidney was prepared for renal micropuncture under inactin/ketamine 
anesthesia as described previously (50). For assessment of single nephron 
glomerular filtration rate, [3H]inulin was infused intravenously. On the 
kidney surface, the last loop of proximal tubules or the distal convolutions 
was identified and punctured for quantitative collections of tubular fluid. 
Tubular fluid volumes were determined from column length in a constant-
bore capillary. The concentrations in tubular fluid of Na+ and K+ were 
determined by a micro-flame photometer (Department of Pharmacology, 
University of Tübingen, Germany) (24, 27) and of Ca2+ by a flow-through 
microfluorometer (NanoFlo; World Precision Instruments Inc.) using Fluo-3 
(MoBiTec) for detection (24, 27).
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Statistical analysis
Data are expressed as mean ± SEM. Statistical comparisons were analyzed 
by 1-way ANOVA and Fisher multiple comparison. P < 0.05 was considered 
statistically significant. All analyses were performed using the StatView 
Statistical Package software (Power PC version 4.51; Abacus Concepts Inc.) 
on an iMac computer (Apple Computer Inc.).
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